Respiratory Support in Severely or Critically Ill ICU Patients With COVID-19 in Wuhan, China

Abstract

This case series aimed to describe the clinical characteristics of severely or critically ill patients with COVID-19 and compare the clinical characteristics of patients who received invasive respiratory support with those of patients who received noninvasive respiratory support. We included all confirmed severe or critical illness cases of COVID-19 admitted to the Intensive Care Unit (ICU) of Zhongnan Hospital of Wuhan University, a COVID-19-designated hospital, from January 8 to March 12, 2020. Cases were analyzed for epidemiological, demographic, clinical, APACHE II, SOFA, radiological features and laboratory data. Outcomes of all patients were followed up as of March 12, 2020. This newly emerging virus had caused 55 confirmed severe or critical illness cases in ICU of a COVID-19-designated hospital. Most of the infected patients were men; more than half had underlying diseases, including hypertension, coronary artery disease and diabetes. The median age was 63 years old. Common symptoms at onset of illness were fever, fatigue and dry cough. Five (9.1%) hospitalized patients were presumed to have been infected in the hospital, and 4 (7.3%) health care workers were infected in their work. Of the 55 confirmed severe or critical illness cases, 10 (18.2%) patients died during the follow-up period as of March 12 with the median follow-up period of 28 days (interquartile range 16–35). Nine patients received VV-ECMO for severe respiratory failure and 4 (44.4%) patients died. Moreover, 28 patients received invasive respiratory support and 14 (50.0%) patients died. In this single-center study, 55 severely or critically ill ICU patients were confirmed to have COVID-19 in Wuhan and the overall mortality was 29.1%. Totally 28 (50.9%) of severely or critically ill ICU patients received invasive respiratory support and 14 (50.0%) died during the follow-up period.

Keywords

COVID-19 / SARS-CoV-2 / acute respiratory distress syndrome / intensive care unit / respiratory support

References

[1] ZhuN, ZhangD, WangW, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733

[2] LuH, StrattonCW, TangYW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol, 2020, 92(4): 401-402

[3] HuiDS, IAE, MadaniTA, et al.. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis, 2020, 91: 264-266

[4] PhanLT, NguyenTV, LuongQC, et al.. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med, 2020, 382(9): 872-874

[5] Epidemiology Working Group for NCIP Epidemic ResponseChinese Center for Disease ControlPrevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi (Chinese), 2020, 41(2): 145-151

[6] WangD, HuB, HuC, et al.. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069

[7] SongF, ShiN, ShanF, et al.. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology, 2020, 295(1): 210-217

[8] ChanJF, YuanS, KokKH, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523

[9] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[10] XuZ, ShiL, WangY, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8: 420-422

[11] WangC, HorbyPW, HaydenFG, et al.. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223): 470-473

[12] WareLB, MatthayMA. The acute respiratory distress syndrome. N Engl J Med, 2000, 342(18): 1334-1349

[13] RussellCD, MillarJE, BaillieJK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223): 473-475

[14] FanE, NeedhamDM, StewartTE. Ventilatory management of acute lung injury and acute respiratory distress syndrome. JAMA, 2005, 294(22): 2889-2896

[15] SlutskyAS, RanieriVM. Ventilator-induced lung injury. N Engl J Med, 2013, 369(22): 2126-2136

[16] BrochardL, SlutskyA, PesentiA. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. Am J Respir Crit Care Med, 2017, 195(4): 438-442

[17] BrodieD, SlutskyAS, CombesA. Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review. JAMA, 2019, 322(6): 557-568

[18] FichtnerF, MoererO, Weber-CarstensS, et al.. Clinical Guideline for Treating Acute Respiratory Insufficiency with Invasive Ventilation and Extracorporeal Membrane Oxygenation: Evidence-Based Recommendations for Choosing Modes and Setting Parameters of Mechanical Ventilation. Respiration, 2019, 98(4): 357-372

[19] Yang X, Cai S, Luo Y, et al. Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome: A Multicenter Descriptive Study. Crit Care Med, 2020. doi: https://doi.org/10.1097/CCM.0000000000004447. Online ahead of print